DDInter596 DDInter1435
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Doxorubicin {u} (Compound) treats {v} (Disease) stomach cancer
Doxorubicin {u} (Compound) binds {v} (Gene) AKR1A1
Doxorubicin {u} (Compound) upregulates {v} (Gene) P4HA2
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Anthracyclines
Doxorubicin {u} (Compound) downregulates {v} (Gene) TSKU
Doxorubicin {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABCC10
Doxorubicin (Compound) resembles Daunorubicin (Compound)
Doxorubicin (Compound) treats stomach cancer (Disease)
Doxorubicin (Compound) binds AKR1A1 (Gene)
Doxorubicin (Compound) upregulates P4HA2 (Gene)
Doxorubicin (Compound) is included by Anthracyclines (Pharmacologic Class)
Doxorubicin (Compound) downregulates TSKU (Gene)
Doxorubicin (Compound) causes Mucous membrane disorder (Side Effect)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene)
Doxorubicin (Compound) binds ABCC10 (Gene) and Doxorubicin (Compound) upregulates ABCC10 (Gene)